<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6E02907B2C294C9E9A37C1C3EF0D7677" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2558 IH: Patient Safety and Toxicology Modernization Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2558</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170519">May 19, 2017</action-date><action-desc><sponsor name-id="C001092">Mr. Collins of New York</sponsor> (for himself, <cosponsor name-id="L000576">Mr. Long</cosponsor>, and <cosponsor name-id="P000608">Mr. Peters</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to issue guidance with respect to
			 three-dimensional human tissue models, and for other purposes.</official-title></form>
	<legis-body id="HA8B21D0A34F84CE88F4F798498F9AC9A" style="OLC">
 <section id="H5463EAE069E64E7980DCB5DF9442AD25" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Patient Safety and Toxicology Modernization Act of 2017</short-title></quote>.</text> </section><section id="H2FDB7FA2AD9340F69322440A38ED469B"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
 <paragraph id="HB035C40086E54A3DB365E69068FE975D"><enum>(1)</enum><text display-inline="yes-display-inline">Preclinical testing serves a fundamental role in characterizing the potential risks and benefits associated with regulated medicines and products.</text>
 </paragraph><paragraph id="H3C22F3BDA8584781B044E805E6A4E5B6"><enum>(2)</enum><text display-inline="yes-display-inline">Critical gaps remain in the understanding of the relationship between patient response and preclinical findings.</text>
 </paragraph><paragraph id="HCD9A0D770FD945D48C2ACFD6A27A9180"><enum>(3)</enum><text display-inline="yes-display-inline">Serious, rare, and unexpected adverse events may be observed in clinical trials or postapproval, particularly toxicology effects not identified in animals that may harm human organs.</text>
 </paragraph><paragraph id="HB81DA5D876D74F57B7E24C35FDDEB31F"><enum>(4)</enum><text display-inline="yes-display-inline">Patient efficacy, safety, dosage information, and speedier access to new medicines will benefit from models that are more predictive than animals and that mimic key elements of human organs.</text>
 </paragraph><paragraph id="H719332CF761849D09FCA7957374BB5A4"><enum>(5)</enum><text>A 2011 report by the Food and Drug Administration, entitled <quote>Advancing Regulatory Science at FDA</quote>, prioritized toxicology testing and the development of models of human adverse response as one of the areas of regulatory science where new or enhanced engagement by the agency is essential to the continued success of the public health and regulatory mission of the Food and Drug Administration.</text>
 </paragraph><paragraph commented="no" id="H967285D671ED431EB7A3F9A0B6F582CA"><enum>(6)</enum><text>The Food and Drug Administration’s 2016 draft commitment letter concerning the reauthorization of fees relating to drugs under part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379g">21 U.S.C. 379g</external-xref> et seq.) proposes a process to add new preclinical models that will not be finalized until at least 2021.</text>
 </paragraph><paragraph id="H44C3DBAE2FA64E4C9EA2A9160578CAE9"><enum>(7)</enum><text>Peer-reviewed data is readily available to illustrate the benefits of commercially available human tissue models to improve the drug discovery process by replicating key elements of living human tissue.</text>
 </paragraph><paragraph id="H75995F700A9549B3B378BF1D5EAD83DB"><enum>(8)</enum><text>The Food and Drug Administration should take immediate steps to validate new models, including three-dimensional human tissue models, that improve regulatory decisionmaking in preclinical, clinical, labeling, and postmarket safety and efficacy testing, or other uses by product sponsors.</text>
			</paragraph></section><section id="HEF7385BC95E14AB2914EFE95DAB60705"><enum>3.</enum><header>Guidance with respect to three-dimensional human tissue models</header>
 <subsection id="HE40557D514F34A21A1C18C0A79D16DF3"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than December 31, 2018, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue guidance addressing—</text>
 <paragraph commented="no" id="HA9C8BBAA658446A58C0F1C4BE8E6D650"><enum>(1)</enum><text>the development and use of novel tools for toxicology and efficacy testing, including three-dimensional human tissue models; and</text>
 </paragraph><paragraph commented="no" id="HE4DFBCD72BAD4047B0ECD40ADFB334DE"><enum>(2)</enum><text>the use of three-dimensional human tissue models for preclinical, clinical, and postmarket safety and efficacy testing, labeling, or other uses by product sponsors.</text>
 </paragraph></subsection><subsection id="HD0541F55A1BD4EB999B3BA8C520E48D3"><enum>(b)</enum><header>Periodic updates</header><text>The Secretary shall periodically update the guidance issued under subsection (a).</text> </subsection></section><section commented="no" id="H18A8CF4C2E2548E0AFE9EBDDCC5FED5D"><enum>4.</enum><header>Rule of construction</header><text display-inline="no-display-inline">Nothing in this Act shall be construed to prohibit or limit the use of three-dimensional human tissue models by product sponsors with respect to—</text>
 <paragraph commented="no" id="H1B675A7B489144DDB9CF8B5806DF2A57"><enum>(1)</enum><text>obtaining approval or licensure of a drug or biological product, including a combination product, under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>); or</text>
 </paragraph><paragraph commented="no" id="H84C0DA2D60EF44F58BEFE75D542141C8"><enum>(2)</enum><text>meeting the requirements of a regulatory decision issued by the Secretary of Health and Human Services.</text>
 </paragraph></section><section id="H17304418287142DDAB393DD5C18BD86A"><enum>5.</enum><header>Definitions</header><text display-inline="no-display-inline">In this Act:</text> <paragraph id="H4EAF5C552C41493AA215CDC9D615C532"><enum>(1)</enum><header>Biological product</header><text>The term <quote>biological product</quote> has the meaning given such term in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>).</text>
 </paragraph><paragraph id="H88F5327E7DD549429B3328F253BED236"><enum>(2)</enum><header>Combination product</header><text>The term <quote>combination product</quote> means a combination product described in section 503(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(g)</external-xref>).</text>
 </paragraph><paragraph id="HFEAAB81AA8684628840CE6AADD276804"><enum>(3)</enum><header>Drug</header><text>The term <quote>drug</quote> has the meaning given such term in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text>
 </paragraph><paragraph id="H0BAA613730CE47A685A811B9F8D5DB09"><enum>(4)</enum><header>Three-dimensional human tissue model</header><text display-inline="yes-display-inline">The term <quote>three-dimensional human tissue model</quote> means a three-dimensional model that—</text> <subparagraph id="H0937B7402A994065B8DBD75F1D0AB734"><enum>(A)</enum><text display-inline="yes-display-inline">approximates human tissue composition and physiology using spatially controlled deposition of adult human cells or cell-containing materials in user-defined, geometric patterns;</text>
 </subparagraph><subparagraph id="H0E525550FDCB4616995A6F17D9FA4044"><enum>(B)</enum><text>can be used to detect toxicity that is not identifiable in animal models;</text> </subparagraph><subparagraph id="H180B05F6CCCE4D35AE89FF274A0E2492"><enum>(C)</enum><text>can be used to test the efficacy of a drug that is not possible or not able to be sufficiently tested in an animal model; and</text>
 </subparagraph><subparagraph id="HBC0149C2CE8F42E681D855CAB64AEEB4"><enum>(D)</enum><text>can predict toxicity in clinical testing or detect toxicity in known clinical failures.</text> </subparagraph></paragraph></section></legis-body></bill> 

